Matej Mikulic
Research expert covering health, pharma & medtech
Biotechnology in pharma worldwide - Statistics & Facts
Biotechnology is steadily reshaping the pharmaceutical industry, both in scale and technological relevance. Global prescription drug revenues are projected to reach around $1.2 trillion in 2025, with expectations to surpass $1.7 trillion by 2030, reflecting sustained demand for advanced therapies. Within this market, biotech-based medicines are gaining share, accounting for roughly half of pharmaceutical sales in 2025, while conventional drugs continue to decline proportionally. This shift is driven by the growing importance of targeted treatments, including biologics and orphan drugs, which address complex and rare diseases more effectively than traditional approaches.
Strong growth in biotech products and pipelines
The commercial success of biotechnology is reflected in rising drug sales and a robust development pipeline. Global biotech drug sales have expanded significantly, reaching an estimated $458 billion in 2024, up from just under $150 billion a decade earlier. At the same time, innovation is accelerating across modalities such as monoclonal antibodies and recombinant therapies, with pipeline assets expected to generate substantial future revenues. For example, monoclonal antibody drugs alone are projected to deliver nearly $325 billion in revenue by 2030. New modalities are generally gaining prominence, with their share of pipeline value expected to reach about 60 percent by 2030, highlighting a structural shift toward next-generation therapies.Â
Innovation ecosystems and investment momentum
Biotechnology’s expansion is supported by strong ecosystems and sustained investment activity. The United States leads globally, with around 3,200 dedicated biotech companies in 2023, far ahead of other countries. Financial backing remains substantial despite market fluctuations, as the industry in the U.S. and Europe raised approximately $73 billion in total capital in 2024, including venture funding and public offerings. Emerging segments such as gene editing and mRNA therapies further illustrate innovation momentum, with markets like CRISPR expected to expand rapidly over the next decade. Together, these factors underline biotechnology’s role as one of the most research-intensive and investment-driven sectors in the global economy.
Expert insight
Biotechnology is transitioning from a high-growth niche into a structurally dominant force within the pharmaceutical industry, supported by both strong commercial performance and a deep innovation pipeline. The shift toward advanced modalities—such as gene editing, mRNA, and cell therapies—signals a long-term transformation in how diseases are treated, moving from broad-spectrum drugs to highly targeted interventions.
This trend is echoed by broader industry analyses, suggesting that AI-driven drug discovery is increasingly reshaping biopharma R&D, with machine learning accelerating target identification and improving development efficiency. Similarly, advances in generative AI are expected to enhance precision medicine approaches, enabling better patient stratification and more effective therapies.
Looking ahead, the convergence of biotechnology and digital technologies is likely to define the next decade of healthcare innovation. While challenges such as high development costs and regulatory complexity remain, the combination of scientific breakthroughs and technological acceleration positions biotech to drive sustained industry growth—particularly in oncology, rare diseases, and personalized treatments.
